In a previous biomarker analysis of tumor tissues from PALOMA-2, no predictive biomarker was associated with lack of benefit from palbociclib plus letrozole treatment, but higher CDK4 expression was identified as a marker of resistance to treatment with letrozole alone [27, 31]. This evidence concerns the gene CDK4 and neoplasm.